NeuroOne Medical Votes on Shareholder Matters
Ticker: NMTC · Form: 8-K · Filed: Feb 14, 2025 · CIK: 1500198
| Field | Detail |
|---|---|
| Company | Neuroone Medical Technologies CORP (NMTC) |
| Form Type | 8-K |
| Filed Date | Feb 14, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
NeuroOne held shareholder votes on Feb 14, 2025 - expect updates on company direction.
AI Summary
NeuroOne Medical Technologies Corporation filed an 8-K on February 14, 2025, to report on matters submitted to a vote of its security holders. The filing details events that occurred on or before February 14, 2025, related to shareholder decisions.
Why It Matters
This filing indicates that important decisions requiring shareholder approval were made or presented, which could impact the company's future direction and governance.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of shareholder voting matters and does not inherently present new financial or operational risks.
Key Players & Entities
- NeuroOne Medical Technologies Corporation (company) — Registrant
- February 14, 2025 (date) — Date of Report
FAQ
What specific matters were submitted to a vote of NeuroOne Medical Technologies Corporation's security holders?
The filing states that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on February 14, 2025.
What is the principal executive office address for NeuroOne Medical Technologies Corporation?
The principal executive office is located at 7599 Anagram Dr., Eden Prairie, MN 55344.
What is the company's state of incorporation?
The company is incorporated in Delaware.
What is the IRS Employer Identification Number for NeuroOne Medical Technologies Corporation?
The IRS Employer Identification Number is 27-0863354.
Filing Stats: 740 words · 3 min read · ~2 pages · Grade level 16.9 · Accepted 2025-02-14 16:15:52
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share NMTC The Nasdaq Stock Mar
Filing Documents
- ea0231253-8k_neuroone.htm (8-K) — 31KB
- 0001213900-25-014281.txt ( ) — 199KB
- nmtc-20250214.xsd (EX-101.SCH) — 3KB
- nmtc-20250214_lab.xml (EX-101.LAB) — 33KB
- nmtc-20250214_pre.xml (EX-101.PRE) — 22KB
- ea0231253-8k_neuroone_htm.xml (XML) — 3KB
07. Submission of Matters to a Vote of Security
Item 5.07. Submission of Matters to a Vote of Security Holders. At the annual meeting (the "Annual Meeting") of stockholders of NeuroOne Medical Technologies Corporation (the "Company") on February 14, 2025, stockholders (i) elected one Class II director to the Company's Board of Directors, to serve a three-year term until the 2028 annual meeting of stockholders, (ii) ratified the appointment of Baker Tilly U.S., LLP as the Company's independent registered public accounting firm for the fiscal year ending September 30, 2025, (iii) approved an amendment to the Company's Certificate of Incorporation to effect a reverse stock split of the Company's outstanding common stock at a ratio in the range of 1-for-2 to 1-for-15 to be determined by the Company's Board of Directors, (iv) approved the NeuroOne Medical Technologies Corporation 2025 Equity Incentive Plan, and (v) authorized one or more adjournments of the Annual Meeting to solicit additional proxies in the event there are insufficient votes to approve Proposal 3. Proposals are described in detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on January 21, 2025, as supplemented on February 5, 2025 and February 7, 2025. A total of 18,117,638 shares of the Company's common stock were present at the meeting in person or by proxy, which represents approximately 58.7% of the shares of common stock outstanding as of the record date for the Annual Meeting. The results of the voting are shown below: Proposal 1—Election of Directors Class II Nominee Votes For Votes Withheld Broker Non-Votes David Rosa 11,724,206 381,677 6,011,755 Proposal 2—Ratification of Appointment of Independent Registered Public Accounting Firm Votes For Votes Against Votes Abstain 18,080,780 7,381 29,477 Proposal 3—Approval of an Amendment to the Company's Certificate of Incorporation to effect a reverse stock split of the Company's outstanding common stock at a ratio in the ran